Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathways

BMC Research Notes

János Nemcsik¹  László Kalabay¹  Andrea László¹ 

[1] Department of Family Medicine, Semmelweis University, Kútvölgyi str. 4, Budapest, 1125, Hungary

关键词: Creatine kinase;    Myopathy;    Statin-fibrate combination therapy;    Exercise;    Metabolic syndrome;   

Others  :  1144800
DOI  :  10.1186/1756-0500-6-52

 received in 2012-12-06, accepted in 2013-01-29,  发布年份 2013

【 摘 要 】

Background

Lifestyle modifications including exercise are beneficial and fundamentally part of the therapy of metabolic syndrome, although in most of the cases medical interventions are also required to reach the target values in the laboratory parameters. Statin and fibrate combination therapy is considered to be safe and effective in dyslipidaemia and metabolic syndrome. However, increased physical activity can enhance the statin and fibrate-associated myopathy. Myositis and the rare but life-threatening rhabdomyolysis are causing a conflict between exercise and statin-fibrate therapy, which is yet to be resolved.

Case presentation

We present a case of a 43-year-old Caucasian man with metabolic syndrome who had the side-effect of exercise and drug-associated myositis. The patient had only transient moderate complaints and rhabdomyolysis could be avoided with the one-month creatine kinase control, a test which is not recommended routinely by the new guidelines.

Conclusions

We would like to turn the spotlight on the possible complications of statin-fibrate therapy and exercise, when strict follow-up is recommended. In this condition high number of patients can be affected and the responsibility of general practitioners is accentuated.

【 授权许可】

   
2013 László et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Alberti KG, Zimmer P, Shaw J, IDF Epidemiology Task Force Consensus Group: The metabolic syndrome - a new worldwide definition. Lancet 2005, 366(9491):1059-62.
• [2]Warburton DE, Nicol CW, Bredin SS: Health benefits of physical activity: the evidence. Cmaj 2006, 174(6):801-809.
• [3]Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, et al.: Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002, 347(19):1483-1492.
• [4]Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, et al.: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Hear J 2011, 32(14):1769-1818.
• [5]Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ: Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin 2007, 23(3):553-563.
• [6]de Sauvage Nolting PR, Buirma RJ, Hutten BA, Kastelein JJ: Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]). Am J Cardiol 2002, 90(2):181-184.
• [7]Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G: A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 2003, 17(5–6):459-465.
• [8]Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114(25):2788-2797.
• [9]Tomlinson SS, Mangione KK: Potential adverse effects of statins on muscle. Phys Ther 2005, 85(5):459-465.
• [10]Sniderman AD: Is there value in liver function test and creatine phosphokinase monitoring with statin use? Am J Cardiol 2004, 94(9A):30F-34F.
• [11]Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD: Molecular basis of statin-associated myopathy. Atherosclerosis 2009, 202(1):18-28.
• [12]Dirks AJ, Jones KM: Statin-induced apoptosis and skeletal myopathy. Am J Physiol 2006, 291(6):C1208-1212.
• [13]Ucar M, Mjorndal T, Dahlqvist R: HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000, 22(6):441-457.
• [14]Omar MA, Wilson JP: FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002, 36(2):288-295.
• [15]Bruckert E, Hayem G, Dejager S, Yau C, Begaud B: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther 2005, 19(6):403-414.
• [16]Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J: Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005, 95(4):462-468.
• [17]Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH: Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. Am J Cardiovasc Drugs 2010, 10(3):175-186.
• [18]McClure DL, Valuck RJ, Glanz M, Murphy JR, Hokanson JE: Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J Clin Epidemiol 2007, 60(8):812-818.
• [19]Bruno-Joyce J, Dugas JM, MacCausland OE: Cerivastatin and gemfibrozil-associated rhabdomyolysis. Ann Pharmacother 2001, 35(9):1016-1019.
• [20]Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH: Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis 2004, 177(1):183-188.
• [21]Davidson MH, Armani A, McKenney JM, Jacobson TA: Safety considerations with fibrate therapy. Am J Cardiol 2007, 99(6A):3C-18C.
• [22]Mascitelli L, Pezzetta F: Physical activity in statin-treated patients. Int J Cardiol 2009, 134(1):136-137.
• [23]Sinzinger H, O'Grady J: Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004, 57(4):525-528.
• [24]Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, et al.: European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(2):E1-40.
• [25]LaRosa JC: Means and ends of statins and low-density lipoprotein cholesterol lowering. J Am Coll Cardiol 2007, 50(5):419-420.
• [26]Domanski MJ: Primary prevention of coronary artery disease. N Engl J Med 2007, 357(15):1543-1545.
• [27]Mascitelli L, Pezzetta F: Statins for primary prevention of coronary artery disease. Lancet 2007, 369(9567):1078-1079. author reply 1079
• [28]Jones PH, Davidson MH: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005, 95(1):120-122.
• [29]Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR: Lovastatin increases exercise-induced skeletal muscle injury. Metab Clin Exp 1997, 46(10):1206-1210.
• [30]Brancaccio P, Maffulli N, Limongelli FM: Creatine kinase monitoring in sport medicine. Br Med Bull 2007, 81–82:209-230.
• [31]Clarkson PM, Kearns AK, Rouzier P, Rubin R, Thompson PD: Serum creatine kinase levels and renal function measures in exertional muscle damage. Med Sci Sports Exerc 2006, 38(4):623-627.
• [32]Kearns AK, Bilbie CL, Clarkson PM, White CM, Sewright KA, O'Fallon KS, Gadarla M, Thompson PD: The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. Atherosclerosis 2008, 200(1):121-125.
• [33]Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, Coe JW: Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 2006, 34(1):121-30.
• [34]Corsini A, Bellosta S, Davidson MH: Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 2005, 96(9A):44K-49K. discussion 34K-35K
• [35]Van Peer ASE, Woestenborghs R: Clinical pharmacokinetics of nebivolol. A review. Drug Invest 1991, 3(Suppl. 1):25-30.
• [36]Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ: CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics 2007, 17(9):695-707.
• [37]Thompson PD, Clarkson PM, Rosenson RS: An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97(8A):69C-76C.